Table: AnGes MG -9-MTH group results
Oct 24 (Reuters)-
AnGes MG Inc
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2016 Sep 30, 2015 Dec 31, 2016
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 256 mln 320 mln 400 mln
(-19.9 pct) (+13.6 pct)
Operating loss 3.76 loss 3.03 loss 6.40
Recurring loss 3.81 loss 2.95 loss 6.40
Net loss 3.82 loss 3.01 loss 6.40
EPS loss 62.66 yen loss 54.41 yen loss 100.88 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - AnGes MG Inc.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001